#Vietnam #GC Biopharma #Yongin #BARYCELA #Varicella Vaccine

GC Biopharma's Successful Launch of BARYCELA in Vietnam

GC Biopharma, a leading South Korean pharmaceutical manufacturer, has marked a significant milestone with the recent marketing authorization of its varicella vaccine, BARYCELA, in Vietnam. This achievement, granted by the Drug Administration of Vietnam (DAV), underscores the company's strategic approach to expanding its market presence in Southeast Asia.

The journey for BARYCELA began with its initial domestic approval in 2020, followed by the World Health Organization's Pre-Qualification (PQ) status in 2023. These steps were crucial in enabling GC Biopharma to establish a foothold in the global market. The company has been executing a dual-track strategy, focusing on both global procurement channels and direct engagement with local markets.

In order to secure the necessary approval in Vietnam, GC Biopharma conducted local clinical trials to validate the vaccine's safety and efficacy. Given that BARYCELA is primarily administered to children, achieving rigorous quality standards was paramount. The DA's decision reflects the company’s commitment to adhering to the increasing regulatory expectations within the region.

A Growing Market for Vaccines in Vietnam

The significance of this approval becomes even more evident when examining the landscape of Vietnam's private vaccine market. Between 2018 and 2021, the market experienced a remarkable compound annual growth rate (CAGR) of 32%, pushing its estimated value towards $300 million in 2021. Varicella vaccines alone accounted for nearly 10% of this burgeoning sector, driven by an increasing demand for private vaccinations—a trend that GC Biopharma aims to capitalize on.

"This marketing authorization represents more than just an export of a product; it signifies our localization strategy and is a significant leap towards our growth in Southeast Asia," stated Jae Woo Lee, Head of the Development Department at GC Biopharma. "We are committed to reinforcing our position as a trusted vaccine brand by meeting clinical and quality standards that align with global expectations."

To facilitate its operations in Vietnam, GC Biopharma is leveraging its local affiliate to engage directly in sales activities, which is crucial given the private market-oriented vaccine distribution system in the country. This approach allows the company to stabilize annual revenue and successfully navigate the complexities of the local market.

Innovation Behind BARYCELA

BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. One of its standout features is the absence of antibiotics in its production, which is indicative of a fully aseptic manufacturing process. Furthermore, the vaccine enjoys high viral titer and manufacturing yield, promising both safety and efficacy in immunization efforts.

As GC Biopharma continues to expand its global footprint, the company remains committed to pushing the boundaries of innovation in biopharmaceuticals. With over fifty years of experience in developing and manufacturing vaccines and plasma derivatives, GC Biopharma is focused on advancing healthcare solutions that respond to future medical needs. The company is also actively investing in research to explore therapeutics for rare diseases alongside immunology and inflammation treatments.

In conclusion, GC Biopharma's success in obtaining marketing authorization for BARYCELA in Vietnam is a major step forward in its expansion strategy throughout Southeast Asia. As they continue to innovate and engage with local markets, the company is poised to make significant contributions to public health initiatives in the region.

For more information about GC Biopharma and its product offerings, visit GC Biopharma's official website.